Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 6/20 | 0.72 |
| ▸ | CDK8 | P49336 | 6/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | HTT | P42858 | 2/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | GLA | P06280 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.67 |
| ▸ | HTR1A | P08908 | 5/20 | 0.51 |
| ▸ | ADRA1D | P25100 | 5/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.51 |
| ▸ | ADRA1B | P35368 | 5/20 | 0.51 |
| ▸ | EGFR | P00533 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6598616 | 0.86 | EGFR (0.63) | CCNCCDK8LMNAHTTKDM4E | |
| SCHEMBL21750454 | 0.84 | CCNC (1.00) | CCNCCDK8LMNAHTTKDM4E | |
| SCHEMBL21750458 | 0.84 | CCNC (1.00) | CCNCCDK8LMNAHTTKDM4E | |
| SCHEMBL7500529 | 0.84 | CCNC (0.72) | CCNCCDK8LMNAHTTKDM4E | |
| SCHEMBL7502818 | 0.84 | HTR1A (0.74) | CCNCCDK8LMNAHTTKDM4E | |
| SCHEMBL21750461 | 0.84 | CCNC (1.00) | CCNCCDK8LMNAHTTKDM4E | |
| SCHEMBL7502035 | 0.83 | HTR1A (0.75) | CCNCCDK8LMNAHTTKDM4E | |
| SCHEMBL7505681 | 0.83 | CCNC (0.70) | CCNCCDK8LMNAHTTKDM4E | |
| SCHEMBL23202824 | 0.82 | CCNC (0.55) | CCNCCDK8LMNAHTTKDM4E | |
| SCHEMBL30827865 | 0.82 | CCNC (0.55) | CCNCCDK8LMNAHTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11014906-B2 | Quinoline-based compounds and methods of inhibiting CDK8/19 | UNIVERSITY OF SOUTH CAROLINA (US) | 2021-05-25 | — | — | US | claimed |
| US-20200062728-A1 | QUINOLINE-BASED COMPOUNDS AND METHODS OF INHIBITING CDK8/19 | UNIVERSITY OF SOUTH CAROLINA (US) | 2020-02-27 | — | — | US | claimed |
| US-12281080-B2 | Quinoline-based compounds and methods of inhibiting CDK8/19 | UNIVERSITY OF SOUTH CAROLINA (US) | 2025-04-22 | — | — | US | disclosed |
| US-20210276956-A1 | QUINOLINE-BASED COMPOUNDS AND METHODS OF INHIBITING CDK8/19 | UNIVERSITY OF SOUTH CAROLINA (US) | 2021-09-09 | — | — | US | disclosed |
| US-20210276956-A1 | QUINOLINE-BASED COMPOUNDS AND METHODS OF INHIBITING CDK8/19 | UNIVERSITY OF SOUTH CAROLINA (US) | 2021-09-09 | — | — | US | disclosed |
| US-11014906-B2 | Quinoline-based compounds and methods of inhibiting CDK8/19 | UNIVERSITY OF SOUTH CAROLINA (US) | 2021-05-25 | — | — | US | disclosed |
| US-11014906-B2 | Quinoline-based compounds and methods of inhibiting CDK8/19 | UNIVERSITY OF SOUTH CAROLINA (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200062728-A1 | QUINOLINE-BASED COMPOUNDS AND METHODS OF INHIBITING CDK8/19 | UNIVERSITY OF SOUTH CAROLINA (US) | 2020-02-27 | — | — | US | disclosed |
| US-20200062728-A1 | QUINOLINE-BASED COMPOUNDS AND METHODS OF INHIBITING CDK8/19 | UNIVERSITY OF SOUTH CAROLINA (US) | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062728-A1 | QUINOLINE-BASED COMPOUNDS AND METHODS OF INHIBITING CDK8/19 | CDK8, CDK9, CDK19 | CCNC 34/4885CDK8 1/4885LMNA 544/4885 |
| US-11014906-B2 | Quinoline-based compounds and methods of inhibiting CDK8/19 | CDK8, CDK9, CDK19 | CCNC 35/4885CDK8 1/4885LMNA 588/4885 |
| US-12281080-B2 | Quinoline-based compounds and methods of inhibiting CDK8/19 | CDK8, CDK9, CDK19 | CCNC 35/4885CDK8 1/4885LMNA 588/4885 |
| US-20210276956-A1 | QUINOLINE-BASED COMPOUNDS AND METHODS OF INHIBITING CDK8/19 | CDK8, CDK9, CDK19 | CCNC 34/4885CDK8 1/4885LMNA 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.